GALLIUM Trial: Safety Information

Common adverse reactions (≥10% incidence and ≥2% greater in the GAZYVA arm), in patients with previously untreated NHL 1

A randomized, open-label multicenter trial (GALLIUM) evaluated the safety of GAZYVA as compared to rituximab product in 1,385 patients with previously untreated follicular lymphoma (86%) or marginal zone lymphoma (14%).

Common new or worsening laboratory abnormalities (≥10% incidence and ≥2% greater in the GAZYVA arm) in patients with previously untreated NHL1

A randomized, open-label multicenter trial (GALLIUM) evaluated the safety of GAZYVA as compared to rituximab product in 1,385 patients with previously untreated follicular lymphoma (86%) or marginal zone lymphoma (14%).

GAZYVA monotherapy investigator-reported adverse reactions 1

  • The common adverse reactions (incidence ≥10%) observed at least 2% more with GAZYVA were upper respiratory tract infection (40%), cough (23%), musculoskeletal pain (20%), neutropenia (19%) and herpesvirus infection (13%)

GAZYVA monotherapy hematological laboratory abnormalities 1

  • New-onset Grade 3 or 4 neutropenia was reported in 21% of patients in the GAZYVA arm (Grade 4, 10%) and 17% of patients in the rituximab product arm (Grade 4, 9%)

Adverse events leading to treatment withdrawal 1

  • 18% in the GAZYVA arm vs 15% in the rituximab arm